Immunovant, Inc. — Director's Dealing 2021

Mar 31, 2021

SEC Form 4/A — Form 4/A

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2021-03-19

Reporting Person: Jain Rita (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-19	Common Stock	A	97600	—	Acquired	117600	Direct
2021-03-19	Common Stock	A	11765	—	Acquired	129365	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-19	Stock Option (right to buy)	$17.0	A	342300	Acquired	2031-03-19	Common Stock (342300.0)	Direct

Footnotes

F1: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

F3: The original Form 4, filed on March 23, 2021, is being amended by this Form 4 amendment solely to correct an administrative error related to the disclosure of the vesting schedule for 11,765 RSUs. These RSUs vest in their entirety six months after the date of grant on September 19, 2021, subject to the Reporting Person providing continuous service to the Issuer as of such date.

F4: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.